L-fucose (AVTX-803)
/ Avalo Therap
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 05, 2024
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=2 | Recruiting | Sponsor: AUG Therapeutics | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Genetic Disorders • Primary Immunodeficiency • SLC35C1
March 05, 2024
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=4 | Recruiting | Sponsor: AUG Therapeutics | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Dec 2023 ➔ Sep 2024
Trial completion date • Trial primary completion date • Genetic Disorders • Primary Immunodeficiency • SLC35C1
July 21, 2023
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=2 | Recruiting | Sponsor: Avalo Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Primary Immunodeficiency • SLC35C1
March 03, 2023
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=2 | Not yet recruiting | Sponsor: Avalo Therapeutics, Inc.
New P3 trial • Genetic Disorders • Primary Immunodeficiency
February 10, 2023
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=4 | Recruiting | Sponsor: Avalo Therapeutics, Inc. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Genetic Disorders • Primary Immunodeficiency
August 05, 2022
The Primary Objective of This Study is to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=4 | Recruiting | Sponsor: Avalo Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Primary Immunodeficiency
July 18, 2022
The Primary Objective of This Study is to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
(clinicaltrials.gov)
- P3 | N=4 | Not yet recruiting | Sponsor: Avalo Therapeutics, Inc.
New P3 trial • Genetic Disorders • Primary Immunodeficiency
1 to 7
Of
7
Go to page
1